Cara Therapeutics has engaged Piper Sandler & Co. to act as its financial advisor for the process of exploring and reviewing strategic alternatives. There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or as to the timing of any such agreements or transactions. Cara Therapeutics does not intend to discuss or disclose further developments regarding the exploration of strategic alternatives unless and until its Board of Directors has approved a specific action or otherwise determined that further disclosure is appropriate or required by law. As of March 31, 2024, the Company had approximately $70 million in cash, cash equivalents, and marketable securities.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CARA:
- Biotech Alert: Searches spiking for these stocks today
- Cara Therapeutics announces 70% workforce reduction
- Chipotle, McDonald’s initiated: Wall Street’s top analyst calls
- Needham downgrades Cara Therapeutics to Hold on lack of pipeline
- Cara Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue